167 related articles for article (PubMed ID: 30917927)
1. Safety and efficacy of the human neutrophil elastase inhibitor BAY 85-8501 for the treatment of non-cystic fibrosis bronchiectasis: A randomized controlled trial.
Watz H; Nagelschmitz J; Kirsten A; Pedersen F; van der Mey D; Schwers S; Bandel TJ; Rabe KF
Pulm Pharmacol Ther; 2019 Jun; 56():86-93. PubMed ID: 30917927
[TBL] [Abstract][Full Text] [Related]
2. Phase II study of a neutrophil elastase inhibitor (AZD9668) in patients with bronchiectasis.
Stockley R; De Soyza A; Gunawardena K; Perrett J; Forsman-Semb K; Entwistle N; Snell N
Respir Med; 2013 Apr; 107(4):524-33. PubMed ID: 23433769
[TBL] [Abstract][Full Text] [Related]
3. Efficacy, safety and effect on biomarkers of AZD9668 in cystic fibrosis.
Elborn JS; Perrett J; Forsman-Semb K; Marks-Konczalik J; Gunawardena K; Entwistle N
Eur Respir J; 2012 Oct; 40(4):969-76. PubMed ID: 22267768
[TBL] [Abstract][Full Text] [Related]
4. Phase 2 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis.
Chalmers JD; Haworth CS; Metersky ML; Loebinger MR; Blasi F; Sibila O; O'Donnell AE; Sullivan EJ; Mange KC; Fernandez C; Zou J; Daley CL;
N Engl J Med; 2020 Nov; 383(22):2127-2137. PubMed ID: 32897034
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic/Pharmacodynamic Evaluation of the Dipeptidyl Peptidase 1 Inhibitor Brensocatib for Non-cystic Fibrosis Bronchiectasis.
Chalmers JD; Usansky H; Rubino CM; Teper A; Fernandez C; Zou J; Mange KC
Clin Pharmacokinet; 2022 Oct; 61(10):1457-1469. PubMed ID: 35976570
[TBL] [Abstract][Full Text] [Related]
6. Dipeptidyl peptidase-1 inhibition with brensocatib reduces the activity of all major neutrophil serine proteases in patients with bronchiectasis: results from the WILLOW trial.
Cipolla D; Zhang J; Korkmaz B; Chalmers JD; Basso J; Lasala D; Fernandez C; Teper A; Mange KC; Perkins WR; Sullivan EJ
Respir Res; 2023 May; 24(1):133. PubMed ID: 37198686
[TBL] [Abstract][Full Text] [Related]
7. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis.
Bilton D; Daviskas E; Anderson SD; Kolbe J; King G; Stirling RG; Thompson BR; Milne D; Charlton B;
Chest; 2013 Jul; 144(1):215-225. PubMed ID: 23429964
[TBL] [Abstract][Full Text] [Related]
8. Freezing the Bioactive Conformation to Boost Potency: The Identification of BAY 85-8501, a Selective and Potent Inhibitor of Human Neutrophil Elastase for Pulmonary Diseases.
von Nussbaum F; Li VM; Allerheiligen S; Anlauf S; Bärfacker L; Bechem M; Delbeck M; Fitzgerald MF; Gerisch M; Gielen-Haertwig H; Haning H; Karthaus D; Lang D; Lustig K; Meibom D; Mittendorf J; Rosentreter U; Schäfer M; Schäfer S; Schamberger J; Telan LA; Tersteegen A
ChemMedChem; 2015 Jul; 10(7):1163-73. PubMed ID: 26083237
[TBL] [Abstract][Full Text] [Related]
9. A randomised, placebo-controlled, dose-finding study of AZD9668, an oral inhibitor of neutrophil elastase, in patients with chronic obstructive pulmonary disease treated with tiotropium.
Vogelmeier C; Aquino TO; O'Brien CD; Perrett J; Gunawardena KA
COPD; 2012 Apr; 9(2):111-20. PubMed ID: 22458939
[TBL] [Abstract][Full Text] [Related]
10. Aztreonam for inhalation solution in patients with non-cystic fibrosis bronchiectasis (AIR-BX1 and AIR-BX2): two randomised double-blind, placebo-controlled phase 3 trials.
Barker AF; O'Donnell AE; Flume P; Thompson PJ; Ruzi JD; de Gracia J; Boersma WG; De Soyza A; Shao L; Zhang J; Haas L; Lewis SA; Leitzinger S; Montgomery AB; McKevitt MT; Gossage D; Quittner AL; O'Riordan TG
Lancet Respir Med; 2014 Sep; 2(9):738-49. PubMed ID: 25154045
[TBL] [Abstract][Full Text] [Related]
11. Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial.
Altenburg J; de Graaff CS; Stienstra Y; Sloos JH; van Haren EH; Koppers RJ; van der Werf TS; Boersma WG
JAMA; 2013 Mar; 309(12):1251-9. PubMed ID: 23532241
[TBL] [Abstract][Full Text] [Related]
12. AZD9668, a neutrophil elastase inhibitor, plus ongoing budesonide/formoterol in patients with COPD.
Kuna P; Jenkins M; O'Brien CD; Fahy WA
Respir Med; 2012 Apr; 106(4):531-9. PubMed ID: 22197578
[TBL] [Abstract][Full Text] [Related]
13. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.
Conrad C; Lymp J; Thompson V; Dunn C; Davies Z; Chatfield B; Nichols D; Clancy J; Vender R; Egan ME; Quittell L; Michelson P; Antony V; Spahr J; Rubenstein RC; Moss RB; Herzenberg LA; Goss CH; Tirouvanziam R
J Cyst Fibros; 2015 Mar; 14(2):219-27. PubMed ID: 25228446
[TBL] [Abstract][Full Text] [Related]
14. Digitoxin for Airway Inflammation in Cystic Fibrosis: Preliminary Assessment of Safety, Pharmacokinetics, and Dose Finding.
Zeitlin PL; Diener-West M; Callahan KA; Lee S; Talbot CC; Pollard B; Boyle MP; Lechtzin N
Ann Am Thorac Soc; 2017 Feb; 14(2):220-229. PubMed ID: 28006108
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of high dose N- Acetylcysteine on airway inflammation and quality of life outcomes in adults with bronchiectasis: A randomised placebo-controlled pilot study.
Jayaram L; King PT; Hunt J; Lim M; Park C; Hu E; Dousha L; Ha P; Bartlett JB; Southcott AM; Muruganandan S; Vogrin S; Rees MA; Dean OM; Wong CA
Pulm Pharmacol Ther; 2024 Mar; 84():102283. PubMed ID: 38141851
[TBL] [Abstract][Full Text] [Related]
16. Leukotriene receptor antagonists in children with cystic fibrosis lung disease : anti-inflammatory and clinical effects.
Schmitt-Grohé S; Zielen S
Paediatr Drugs; 2005; 7(6):353-63. PubMed ID: 16356023
[TBL] [Abstract][Full Text] [Related]
17. The role of neutrophils in cystic fibrosis.
Gifford AM; Chalmers JD
Curr Opin Hematol; 2014 Jan; 21(1):16-22. PubMed ID: 24253427
[TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of recombinant alpha(1)-antitrypsin therapy in cystic fibrosis.
Martin SL; Downey D; Bilton D; Keogan MT; Edgar J; Elborn JS;
Pediatr Pulmonol; 2006 Feb; 41(2):177-83. PubMed ID: 16372352
[TBL] [Abstract][Full Text] [Related]
19. A randomised, placebo-controlled study of the CXCR2 antagonist AZD5069 in bronchiectasis.
De Soyza A; Pavord I; Elborn JS; Smith D; Wray H; Puu M; Larsson B; Stockley R
Eur Respir J; 2015 Oct; 46(4):1021-32. PubMed ID: 26341987
[TBL] [Abstract][Full Text] [Related]
20. Effect of long-term, low-dose erythromycin on pulmonary exacerbations among patients with non-cystic fibrosis bronchiectasis: the BLESS randomized controlled trial.
Serisier DJ; Martin ML; McGuckin MA; Lourie R; Chen AC; Brain B; Biga S; Schlebusch S; Dash P; Bowler SD
JAMA; 2013 Mar; 309(12):1260-7. PubMed ID: 23532242
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
